Masato Irisawa

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD K.K. (Japan)

Tokushima University

Masato Irisawa is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, geriatric oncology pharmacotherapy, and programmed death-ligand 1 signaling.

Publications per year

2022–2022

Publications

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

Yasushi Goto, Atsuhisa Tamura, Hirotaka Matsumoto et al. · JTO Clinical and Research Reports · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan

Hiroshi Nokihara, Takashi Kijima, Toshihide Yokoyama et al. · Cancers · 2022 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–2 of 2